
Leidos Hld (LDOS) Stock Forecast & Price Target
Leidos Hld (LDOS) Analyst Ratings
Bulls say
Leidos Holdings Inc. has demonstrated strong financial performance, particularly in its Health & Civil segment, where increased exam volumes have positively impacted margins due to economies of scale. The company's national security revenues saw a substantial 8% year-over-year growth, reaching $2.02 billion, driven by new contract awards and mission support growth, while defense systems revenues increased by 11% year-over-year to $582 million. Furthermore, the notable improvement in EBIT margins from 14.5% in 2023 to 22.5% in 2024, with a projected 24.3% margin in the first half of 2025, highlights Leidos's operational efficiency and financial health, supporting a favorable outlook for the company's stock.
Bears say
The financial outlook for Leidos Holdings Inc. appears negative primarily due to anticipated margin declines in the latter half of 2025 relative to the first half, raising concerns about overall profitability. There are additional risks associated with potential decreases in medical exam volumes, which could further pressure margins in their health services sector, compounded by governmental budget uncertainties. Moreover, factors such as legal challenges to contracts, potential government shutdowns, and international regulatory risks could adversely affect the company's operating results and overall market sentiment.
This aggregate rating is based on analysts' research of Leidos Hld and is not a guaranteed prediction by Public.com or investment advice.
Leidos Hld (LDOS) Analyst Forecast & Price Prediction
Start investing in Leidos Hld (LDOS)
Order type
Buy in
Order amount
Est. shares
0 shares